Kate Wheeler, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1639121056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 749 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations.
Across 749 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Amgen$1K
- Corcept Therapeutics$1K
- Mannkind Corporation$1K
- Tandem Diabetes Care, Inc.$1K
- plus $9K from 54 others
Across 1 payment — averaging $7886.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$8K
What the payments were for
- Food & beverage$16,64698%
- Education$3292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$730
- t:slim X2 Insulin Pump with Control-IQ$680
- Korlym$385
- EVENITY$369
- Ozempic$205
- UNITY DIABETES MANAGEMENT SYSTEM$187
- Omnipod$186
- FreeStyle Libre 2$128
- MOUNJARO$125
- Prolia$125
- Tymlos$122
- RYBELSUS$104
How this compares
$16,974 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 26 | $1,295,710 |
| MounjaroTirzepatide | 383 | $502,545 |
| OzempicSemaglutide | 380 | $454,655 |
| SigniforPasireotide Diaspartate | 12 | $234,391 |
| JardianceEmpagliflozin | 115 | $125,824 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 92 | $110,613 |
| FarxigaDapagliflozin Propanediol | 148 | $109,598 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 84 | $78,816 |
| RybelsusSemaglutide | 74 | $74,739 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 59 | $55,658 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $47,454 |
| TrulicityDulaglutide | 33 | $38,401 |
| HumatropeSomatropin | 14 | $35,843 |
| JanuviaSitagliptin Phosphate | 25 | $30,341 |
| ProliaDenosumab | 17 | $28,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $1,145 | $1,295,71026 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humatrope, Humalog | $1,385 | $582,357451 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,882 | $548,492504 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $327 | $253,265236 claims |
| NovartisSignifor | $51 | $234,39112 claims |
| AstraZenecaFarxiga | $142 | $109,598148 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $895 | $57,99889 claims |
| MerckJanuvia | $132 | $30,34125 claims |
| AmgenProlia | $1,272 | $28,93817 claims |
| AbbVieSynthroid | $293 | $20,238199 claims |
| IBSA Pharma Inc.Tirosint | $325 | $4,27317 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $199 | $4,230420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
- Era ShahAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.